Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines

Wybranietz, W. A.; Prinz, Florian; Spiegel, Martin; Schenk, Andrea; Bitzer, Michael; Gregor, Michael; Lauer, Ulrich M.

doi:10.1002/(sici)1521-2254(199907/08)1:4<265::aid-jgm48>3.0.co;2-d

Cited by 50 publications

(16 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cells expressing MART-1 polypeptides by adenovector infection display MART-1 CTL epitopes [16]; we wanted to determine if, in a similar context, expression of the VP22-MART-1 polypeptide also resulted in efficient presentation of the MART-1 [27][28][29][30][31][32][33][34][35] epitope. A375 melanoma cells infected with Adv-MART-1 and Adv-VP22-MART-1 were used in a CTL activation assay measuring IFN-c release.…”

Section: Recognition Of Adenovirus-infected Cells By Mart-1-specific mentioning

confidence: 99%

“…We show here that the human MART-1 melanoma tumorassociated-but-self antigen [14,15], which has been studied extensively as a potential cancer vaccine antigen [16][17][18][19], can be introduced into the endosomal compartments of DC by intercellular spread of an HSV VP22-MART-1 chimera, such that the A2-restricted MART-1 [27][28][29][30][31][32][33][34][35] CTL epitope is presented and recognized by MART-1 [27][28][29][30][31][32][33][34][35] -specific CTL. Therefore, cross-presentation of a tumor-associated-but-self-antigen can occur by DC in the absence of gene transfer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cross‐presentation of a human tumor antigen delivered to dendritic cells by HSV VP22‐mediated protein translocation

et al. 2004

View full text Add to dashboard Cite

Dendritic cells (DC) capture antigens from apoptotic and/or necrotic tumor cells and crosspresent them to T cells, and various ways of delivering tumor antigens to DC in vitro and in vivo are being pursued. Since fusions of antigenic proteins with the HSV integument protein VP22 are capable of intercellular trafficking, this approach has been exploited for delivery of antigens to antigen-presenting cells. Adenoviral vectors were used to express the tumorassociated-but-self-antigen MART-1 fused to HSV VP22 in MART-1-negative A375 melanoma cells and in DC. When expressed in A375 cells and allowed to spread to DC across a transwell barrier, the VP22-MART-1 fusion protein localized to both early and late endosomal structures of the DC. The DC loaded with the VP22-MART-1 fusion by intercellular trafficking efficiently presented the MART-1 27-35 epitope to MART-1 27-35 -specific CTL. Furthermore, transloaded DC were capable of expanding the population of MART-1 27-35 -specific CTL. Thus, a tumor antigen acquired by intercellular trafficking can be crosspresented by DC. This experimental approach should therefore be useful not only for studying the mechanism of cross-presentation but also for vaccine development.

show abstract

Section: Recognition Of Adenovirus-infected Cells By Mart-1-specific mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cross‐presentation of a human tumor antigen delivered to dendritic cells by HSV VP22‐mediated protein translocation

et al. 2004

View full text Add to dashboard Cite

show abstract

“…This chimera protein behaved essentially like the native protein with respect to expression, localization, and spread to surrounding proliferating cells as well as to terminally differentiated un-transfected cells. [171][172][173] The HIV-1 lentiviral vectors were able to deliver the chimera VP22-EGFP fusion protein from infected target cells to the cytoplasm and nuclei of uninfected cells in vitro and into the mouse brain in vivo. 174 These findings suggest that efficient transfer of therapeutic genes and their protein products (e.g., Protein VP22 or VP22-based fusion proteins) could be achieved with a lentiviral vector.…”

Section: C E L L P E N E T R a T I N G P E P T I D E S D E R I V E mentioning

confidence: 99%

Medium‐sized peptides as built in carriers for biologically active compounds

Hudecz

Bánóczi

Csı́k

2005

Medicinal Research Reviews

View full text Add to dashboard Cite

A growing number of oligopeptides of natural and/or synthetic origin have been described and considered as targeting structures for delivery bioactive compounds into various cell types. This review will outline the discovery of peptide sequences and the corresponding mid-sized oligopeptides with membrane translocating properties and also summarize de novo designed structures possessing similar features. Conjugates and chimera constructs derived from these sequences with covalently attached bioactive peptide, epitope, oligonucleotide, PNA, drug, reporter molecule will be reviewed. A brief note will refer to the present understanding on the uptake mechanism at the end of each section.

show abstract

“…Accordingly, a VP22-p53 fusion protein was used successfully to induce apoptosis in a p53 deficient osteosarcoma cell line (12). To date, VP22 fusion proteins have been shown to spread in several established lines of proliferating cells (13), and we have shown that VP22 can cargo fused GFP into terminally differentiated skeletal muscle cells (14).…”

mentioning

confidence: 92%

A novel approach to induce cell cycle reentry in terminally differentiated muscle cells

et al. 2001

View full text Add to dashboard Cite

During terminal differentiation, skeletal muscle cells permanently retract from the cell cycle. We and others have shown previously that this cell cycle withdrawal is an actively maintained state that can be reversed by transient expression of the SV40 large T antigen. In an attempt to avoid the hazards of gene transfer and the difficulties of regulating transgene expression, we have now used this cellular system as a model to test whether direct protein delivery could constitute a feasible alternative or complementing strategy to gene therapy-based approaches. Taking advantage of the recently described intercellular trafficking properties of the herpes simplex virus I VP22 protein, we have constructed a chimeric VP22-SV40 large T antigen fusion protein and shown that it can spread into terminally differentiated myotubes where it accumulates in the nucleus. This fusion protein retains the ability to override the cell cycle arrest as shown for SV40 large T antigen alone. Our results clearly show that the transduced fusion protein remains capable of inducing S-phase and mitosis in these otherwise terminally differentiated cells and opens now the way to exploit this novel strategy for tissue regeneration.

show abstract

Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines

Cited by 50 publications

References 9 publications

Cross‐presentation of a human tumor antigen delivered to dendritic cells by HSV VP22‐mediated protein translocation

Cross‐presentation of a human tumor antigen delivered to dendritic cells by HSV VP22‐mediated protein translocation

Medium‐sized peptides as built in carriers for biologically active compounds

A novel approach to induce cell cycle reentry in terminally differentiated muscle cells

Contact Info

Product

Resources

About